Products
Clivatuzumab Biosimilar Radiolabelled Antibody (MUC1) for Research
Pre-Made Clivatuzumab biosimilar, Whole mAb Radiolabelled, Anti-MUC1 Antibody: Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-112-1mg | 1mg | |
| GMP-Bios-ab-112-10mg | 10mg | |
| GMP-Bios-ab-112-100mg | 100mg | |
| GMP-Bios-ab-112-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Clivatuzumab biosimilar, Whole mAb Radiolabelled, Anti-MUC1 Antibody: Anti-ADMCKD/ADMCKD1/ADTKD2/CA 15-3/CD227/Ca15-3/EMA/H23AG/KL-6/MAM6/MCD/MCKD/MCKD1/SEC/X/ZD/PEM/PEMT/PUM therapeutic antibody |
| INN Name | Clivatuzumab |
| Target | MUC1 |
| Format | Whole mAb Radiolabelled |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Immunomedics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Pancreatic cancer |
| Development Tech | na |
About target - MUC1
1. Protein Mucin-1
2. Gene MUC1
3. Organism Homo sapiens (Human)
Function
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.
The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.
Miscellaneous
The name KL-6 was originally that of a murine monoclonal antibody reacting with pulmonary adenocarcinoma cell lines and pulmonary epithelial cells. This antibody recognizes a sialylated carbohydrate chain on MUC1.
Caution
O-glycosylation sites are annotated in first sequence repeat only. Residues at similar position are probably glycosylated in all repeats. Experimental sites were determined in a synthetic peptide glycosylated in vitro (PubMed:7744025, PubMed:9597769).
